NCT06093191 (ERASE) is a Phase 4 clinical trial of Tobramycin Inhalant Product in Bronchiectasis Adult, sponsored by Jin-Fu Xu.

Who is sponsoring NCT06093191?

NCT06093191 is sponsored by Jin-Fu Xu.

What drugs are being tested in NCT06093191?

Interventions in NCT06093191: Tobramycin Inhalant Product, Ciprofloxacin 750 MG, Oral ciprofloxacin placebo, Natural saline inhalation.

What condition does NCT06093191 study?

NCT06093191 studies Bronchiectasis Adult, Pseudomonas Aeruginosa Infection.

Is NCT06093191 still recruiting?

NCT06093191 is currently completed. Last updated 17 April 2026.

Last reviewed 2026-04-17 · How we verify

NCT06093191: ERASE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

Completed Phase 4 Last updated 17 April 2026

What this trial tests

Phase 4 trial testing Tobramycin Inhalant Product in Bronchiectasis Adult in 371 participants. Completed in 15 November 2025.

Timeline

18 October 2023

Primary endpoint
28 October 2025

15 November 2025

Quick facts

Lead sponsor	Jin-Fu Xu
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	371
Start date	18 October 2023
Primary completion	28 October 2025
Estimated completion	15 November 2025
Sites	60 locations across China

Drugs / interventions tested

Tobramycin Inhalant Product — full drug profile →
Ciprofloxacin 750 MG — full drug profile →
Oral ciprofloxacin placebo — full drug profile →
Natural saline inhalation — full drug profile →

Conditions studied

Bronchiectasis Adult — all drugs for Bronchiectasis Adult →
Pseudomonas Aeruginosa Infection — all drugs for Pseudomonas Aeruginosa Infection →

Sponsor

Jin-Fu Xu

Who can join

Adults 18 to 80, any sex, with Bronchiectasis Adult or Pseudomonas Aeruginosa Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

People with bronchiectasis are prone to Pseudomonas aeruginosa (PA) infections, which can become chronic and lead to increased death rates and disease severity. Studies from cystic fibrosis suggest that eradication therapy aimed at PA can successfully transition patients to a culture-negative status, providing long-term benefits. Current guidelines for managing bronchiectasis in adults recommend eradicating PA when it is first or newly isolated; however, there is a lack of randomized controlled trials supporting such recommendations. The researchers hypothesize that both oral ciprofloxacin combined with tobramycin inhalation solution and tobramycin inhalation solution alone are superior to no eradication (inhaled saline) in terms of the eradication rate of PA (with eradication defined as negative sputum culture results on two consecutive occasions separated by an interval of 12 weeks or more after the first drug administration).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A phase 4 multicentre, 2×2 factorial randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of tobramycin inhalation solution for <i>Pseudomonas aeruginosa</i> eradication in bronchiectasis: ERASE.
Gao YH, Lu HW, Zheng HZ, Cao C, et al · · 2024 · cited 7× · PMID 38410702 · DOI 10.1183/23120541.00938-2023
Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects.
Dallal Bashi YH, Mairs R, Murtadha R, Kett V. · · 2025 · cited 6× · PMID 39861758 · DOI 10.3390/pharmaceutics17010111

Verify or expand the search:

Other recruiting trials for Bronchiectasis Adult

Currently open trials in the same condition.

NCT07289100 — Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchie · recruiting
NCT06900062 — The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping · recruiting
NCT06820918 — Physiotherapy With Positive Expiratory Pressure (PEP) Bottle in Patients With Bronchiectasis · NA · active not recruiting
NCT06801327 — Comparison Between Conventional Respiratory Physiotherapy and the Simeox Device in Patients With Bronchiectasis · NA · recruiting
NCT06760273 — Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06093191 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jin-Fu Xu
Last refreshed: 17 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06093191.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing